Biomarkers, Neurodevelopment and Preterm Infants
- Conditions
- PretermNeurodevelopmental DisorderEpigenetic Changes
- Interventions
- Other: Observational study
- Registration Number
- NCT02557191
- Lead Sponsor
- Montefiore Medical Center
- Brief Summary
Approximately 2% of neonates in the US are born very preterm. Preterm births are associated with impaired cognitive, language and motor function, and increased risk for autism spectrum disorders. Epidemiological studies indicate a dose-response relationship between gestational age at delivery and cognitive impairments, with the most immature of newborns being the most susceptible to developmental delays. Sensitive and reproducible biomarkers of long-term neurocognitive impairments are currently lacking. The investigators seek to identify epigenetic markers that mediate the relationship between adverse prematurity-related exposures and neurocognitive impairments. The overarching hypothesis of this proposal is that DNA methylation profiles of CD34+ hematopoetic progenitor and stem cells from very preterm infants can be used as a risk-stratifying biomarker for predicting neurocognitive impairment in childhood.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 4
- <32 weeks" gestation
- Born at Weiler Division of Montefiore
- Intraventricular hemorrhage
- Chromosomal abnormalities
- Congenital viral conditions
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 Observational study Preterm infants \<32 weeks gestational age
- Primary Outcome Measures
Name Time Method Brain white matter development 38-42 weeks adjusted age Brain MRI
- Secondary Outcome Measures
Name Time Method Neurodevelopment 18-24 months adjusted age Administration of Bayley Scales of Infant and Toddler Development, 3rd edition
Trial Locations
- Locations (1)
Jack D. Weiler Hospital
🇺🇸Bronx, New York, United States